Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression

Bone Marrow Transplantation volume 55, pages 1817–1820 (2020)Cite this article

Subjects

Multiple myeloma remains one of the most challenging malignancies to treat. There has been a remarkable progress in survival after high-dose chemotherapy and novel agents but even with novel drug combinations that achieve high response rates including MRD-negative remission ultimately most patients will progress. Allogeneic SCT is a potentially curative option for patients, suggested by a plateau effect [1, 2]. But even if some patients obtain a durable remission after allogeneic SCT the majority of patients eventually relapse. It is interesting to note that the majority of these patients retain full donor chimerism at relapse [3], suggesting high-dose chemotherapy with autologous harvested stem cells might be a suitable treatment option for disease control.

Two case reports have been published so far where the investigators used these “pseudo-autologous” peripheral blood stem cells from the patient as stem cell source without immunosuppression with the rationale that this stem cell product had developed tolerance with no or low risk of graft-versus-host disease (GVHD) [4, 5].

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schonland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30:2047–54. https://doi.org/10.1038/leu.2016.101

    Article  CAS  PubMed  Google Scholar 

  2. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121:5055–63. https://doi.org/10.1182/blood-2012-11-469452

    Article  CAS  PubMed  Google Scholar 

  3. Rasche L, Rollig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transplant. 2016;22:1988–96. https://doi.org/10.1016/j.bbmt.2016.08.024

    Article  PubMed  Google Scholar 

  4. Hatsuse M, Taniguchi-Yoshihara K, Yagyu S, Fuchida S, Okano A, Murakami S, et al. Successful treatment with pseudo-autologous bloodstem cell transplantation for an adolescent-onset multiple myeloma whorelapsed after allogenic bone marrow transplantation. Rinsho Ketsueki. 2015;56:428–431. https://doi.org/10.11406/rinketsu.56.428

    Article  PubMed  Google Scholar 

  5. Palfreyman E, Song K, Nantel S. Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:1138 https://doi.org/10.1038/bmt.2013.12

    Article  CAS  PubMed  Google Scholar 

  6. Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921–2. https://doi.org/10.1182/blood-2015-05-647636

    Article  CAS  PubMed  Google Scholar 

  7. Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20:382–6. https://doi.org/10.1016/j.bbmt.2013.11.034

    Article  CAS  PubMed  Google Scholar 

  8. Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22:258–67. https://doi.org/10.1016/j.bbmt.2015.08.025

    Article  PubMed  Google Scholar 

  9. Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19:398–404. https://doi.org/10.1016/j.bbmt.2012.10.008

    Article  CAS  PubMed  Google Scholar 

  10. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103:4362–4. https://doi.org/10.1182/blood-2003-11-3862

    Article  CAS  PubMed  Google Scholar 

  11. Kroger N, Kruger W, Renges H, Zabelina T, Stute N, Jung R, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol. 2001;112:421–3.

    Article  CAS  PubMed  Google Scholar 

  12. Kroger N, Zabelina T, Klyuchnikov E, Kropff M, Pfluger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48:403–7. https://doi.org/10.1038/bmt.2012.142

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Polona Novak, Evgeny Klyuchnikov, Ute-Marie von Pein, Martina Güllstorf, Maximilian Christopeit, Francis Ayuk, Christine Wolschke & Nicolaus Kröger

  2. Clinical Department for Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia

    Polona Novak

  3. Institute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Maria Geffken

Authors
  1. Polona Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evgeny Klyuchnikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ute-Marie von Pein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martina Güllstorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maximilian Christopeit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francis Ayuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Geffken
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christine Wolschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nicolaus Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NK designed the study and wrote the paper. PN analysed data, interpreted results, and wrote the paper. MG prepared CD34 selection. EK, UvP, MG, MC, FA, and CW analysed data, interpreted results, and approved the final version of the paper.

Corresponding author

Correspondence to Nicolaus Kröger.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Novak, P., Klyuchnikov, E., von Pein, UM. et al. Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. Bone Marrow Transplant 55, 1817–1820 (2020). https://doi.org/10.1038/s41409-020-0912-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0912-7

This article is cited by

Search

Advanced search

Quick links